BRIEF published on 11/04/2024 at 11:51, 1 year 11 months ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 11 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 11 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 11 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 11 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 11 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 11 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 11 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 2 years 2 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years 2 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 10/06/2026 at 16:45, 30 minutes ago Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 10/06/2026 at 16:30, 45 minutes ago Snipp Survey Finds AI is Reshaping the Shopper Journey, with 61.8% of AI Users Having Purchased After an AI Recommendation
Published on 10/06/2026 at 15:45, 1 hour 30 minutes ago Stagwell Launches New Global Media Agency, Stagwell Media
Published on 10/06/2026 at 15:00, 2 hours 15 minutes ago Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
Published on 10/06/2026 at 14:31, 2 hours 44 minutes ago Worksport (Nasdaq: WKSP) Books $2.92M August Orders; Annualized Order Run Rate Reaches $35M
Published on 10/06/2026 at 17:08, 6 minutes ago EQS-Adhoc: Bio-Gate AG: Revises Revenue and Earnings Forecast for Fiscal Year 2026
Published on 10/06/2026 at 17:06, 9 minutes ago Bitcoin Group SE: futurum bank AG prepares alternative operating model for Bitcoin.de
Published on 10/06/2026 at 17:05, 10 minutes ago EQS-Adhoc: Bitcoin Group SE: Bafin refuses MiCAR authorisation applied for by futurum bank AG
Published on 10/06/2026 at 16:51, 24 minutes ago EQS-Adhoc: SGL Carbon SE reports preliminary sales and earnings figures for the first nine months and raises its forecast for 2026
Published on 10/06/2026 at 16:35, 40 minutes ago Viola Aleo Ltd: First in Financial Intermediation for Five Consecutive Years
Published on 10/05/2026 at 22:12, 19 hours 3 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 19 hours 3 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 23 hours 2 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 23 hours 2 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 23 hours 15 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
